About 3,328 results

ALLMedicine™ Acute Promyelocytic Leukemia Center

Research & Reviews  1,133 results

Association of insurance types and outcomes in acute promyelocytic leukemia.
Leukemia & Lymphoma; Dhakal P, Joshi U et. al.

Jun 24th, 2022 - Understanding the association between insurance status and survival in an evolving US healthcare system remains a challenge but is essential to address healthcare disparities. We utilized National Cancer Database to evaluate the effects of insuran...

Acute promyelocytic leukemia: Immunophenotype and differential diagnosis by flow cytome...
Cytometry. Part B, Clinical Cytometry; Fang H, Wang SA et. al.

Jun 19th, 2022 - Prompt diagnosis of acute promyelocytic leukemia (APL) is critical for patient care. In this study, we aimed to characterize the immunophenotype of APL and explore immunophenotypic difference between APL and its mimics using flow cytometric analys...

Recurrent non-coding somatic and germline WT1 variants converge to disrupt MYB binding ...
Blood Song H, Liu Y et. al.

Jun 3rd, 2022 - Genetic alternations can occur at non-coding regions, but how they contribute to cancer pathogenesis is poorly understood. Here we established a mutational landscape of cis-regulatory regions (CREs) in acute promyelocytic leukemia (APL) based on w...

see more →

Guidelines  2 results

NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.
Journal of the National Comprehensive Cancer Network : JN... Pollyea DA, Bixby D et. al.

Jan 7th, 2021 - The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regard...

Acute myeloid leukemia, version 2.2013.
Journal of the National Comprehensive Cancer Network : JN... O'Donnell MR, Tallman MS et. al.

Sep 14th, 2013 - These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Acute Myeloid Leukemia and discuss the clinical evidence that support the recommendations. The updates described in this article focus on the acute promyelocyt...

see more →

Drugs  14 results see all →

Clinicaltrials.gov  82 results

Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

May 10th, 2022 - PRIMARY OBJECTIVES: I. Assess whether a combination of all-trans retinoic acid (ATRA [tretinoin]), and arsenic trioxide (ATO) can produce long-term event-free survival in patients with low-risk untreated acute promyelocytic leukemia (APL). II. Ass...

A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia

May 10th, 2022 - OBJECTIVES: Determine the safety and efficacy of "ATO/RIF + ATRA + less intensive chemotherapy" protocol in children with acute promyelocytic leukemia (APL). Compare the safety,efficacy and treatment cost of "RIF + ATRA + less intensive chemother...

Safety and Efficacy Study of Idarubicin Dose Intensification to Treat Acute Myeloid Leukemia

Apr 15th, 2022 - Up to nowadays, a standard induction therapy for acute myeloid leukemia(AML) has consisted of cytarabine 100-200 mg per square meter of body surface area(BSA) per day continuous infusion for 7 days with idarubicin 12 mg per square meter or daunoru...

Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid

Mar 28th, 2022 - Acute myeloid leukemia (AML) is a genetically heterogeneous disease with a highly variable prognosis and an overall high mortality rate. The 5-year overall survival of adult AML patients is less than 50%, and only 20% of elderly patients survive o...

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia

Mar 25th, 2022 - PRIMARY OBJECTIVES: I. To decrease the total anthracycline dose from the best current published results in standard risk childhood acute promyelocytic leukemia (APL) while still maintaining a comparable event-free survival (EFS). SECONDARY OBJECTI...

see more →

News  100 results

FDA Grants Fast Track Status to PRGN-3006 for Relapsed/Refractory AML

May 2nd, 2022 - The FDA has granted a fast track designation to the multigenic autologous CAR T-cell therapy PRGN-3006 for use as a potential therapeutic option in patients with relapsed or refractory acute myeloid leukemia (AML), according to an announcement fro...

Acute Promyelocytic Leukemia: A Subset of Acute Myeloid Leukemia

Apr 14th, 2022 - This transcript has been edited for clarity. Gail J. Roboz, MD: Hi, everyone. My name is Dr Gail Roboz, and welcome to Medscape InDiscussion. Today, we're going to be talking about acute myeloid leukemia (AML) and specifically a subtype of AML, ca...

Good-Risk Acute Myeloid Leukemia

Apr 14th, 2022 - This transcript has been edited for clarity. Gail J. Roboz, MD: Hi, everyone. My name is Dr Gail Roboz. I'm a professor of medicine and director of the leukemia program at Weill Cornell Medicine and the NewYork-Presbyterian Hospital in New York Ci...

Precision medicine: A new approach to AML, other blood cancers
Caleb Rans, PharmD

Dec 12th, 2021 - The emergence of precision medicine has ushered in a groundbreaking era for the treatment of myeloid malignancies, with the ability to integrate individual molecular data into patient care. Over the past decade, insights from research focusing on.

'Shocking' Lack of Lifesaving Leukemia Drug at US Hospitals

Dec 6th, 2021 - A drug crucial for the emergency management of acute promyelocytic leukemia (APL) simply isn't stocked by many US hospitals, according to a recent report in the Journal of the National Comprehensive Cancer Network. The drug — all-trans retinoic ac...

see more →